october 7 visit of bill gates
52 messages over 47 days, 2013-09-26 – 2013-11-13.
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis PROGRAM OF ACTIVITY NIH Visit OF BiLL GATES Octoser 7, 2013 10:15 AM-- 11:00 AM Media Roundtable at Clinical Center (room TBD) 11:05 AM - 11:15 AM Meeting with Dr. Collins (room TBD) 11:15 AM - 12:30 PM Roundtable Discussion with NIH Senior Leadership Medical Board Room, Clinical Center Opening remarks: Francis Collins and Bill Gates Select priorities in global health R&D: state of the science, question to resolve e --HlVand malaria vaccines, and other prevention technologies Lead discussant: Hugh Auchincloss, Principal Deputy Director, NIAID Cliff Lane, Deputy Director for Clinical Research, NIAID Roger Glass, Director, FIC e Understanding the molecular basis of growth and nutrition Lead discussant: Alan Guttmacher, Director, NICHD Greg Germino, Director NIDDK ¢ Point-of-care diagnostics and therapeutics for neglected diseases Lead discussant: Roderic Pettigrew, Director, NIBIB Martha Somerman. Director, NIDCR Chris Austin, Director, NCATS e Integrating NCDs into global health Lead Discussant: Harold Varmus, Director, NCI Gary Gibbons, Director, NHLBI e New partnerships in discovery science: H3Africa and MEPI, the BRAIN initiative Lead Discussant: Eric Green, Director, NHGRI Francis Collins Roger Glass e NIH-PEPAR Implementation Science Partnership Eric Goosby, US Global AIDS Coordinator 12:00 PM-12:30 PM Working Lunch Masur Auditorium, Clinical Center 1:00 PM - 2:00 PM David E. Barmes Global Health Lecture 1:00 PM--- 1:05 PM Introduction by Dr. Collins 1:05 PM -- 1:40 PM Lecture 1:40 PM -- 2:00 PM Q's and A's The C.W. "Bill" Young Center 2:20 PM -- 3:05 PM Innovations in TB Drug Development Clif Barry 3:05 PM -- 3:20 PM Wrap up discussion Dr. Collins and Mr. Gates Chris Wilson Bill and Melinda Gates Foundation Dr. Chris Wilson, director of the Global Health Discovery & Translational Sciences program, leads a team that targets fundamental scientific and technological advances in global health that could lead to new ways to prevent, treat, and diagnose disease. Wilson joined the foundation in 2009 as Deputy Director, Vaccine Discovery and Human Biology, Global Health Discovery. Wilson is a pediatrician and immunologist. He joined the faculty at the University of Washington in 1979 in the Infectious Diseases Division of the Department of Pediatrics and later served as head of the Division of Infectious Diseases, Immunology and Rheumatology. In 1989, he became one of the founding faculty members in the new Department of Immunology, and served as Chairman of the Department of Immunology and head of the graduate program in immunology from 1999-2009. He has also served on a number of national advisory panels, including the Institute of Medicine Vaccine Safety Review Committee (2001-2004) and the National Advisory Council on Child Health and Human Development, the NIH Advisory Committee to the Director, and he co-chaired the NIAID US Immunodeficiency Network Pilot Grant Review Committee. He is an elected fellow of the American Association for the Advancement of Science. Wilson received a bachelor's degree from the University of California, Irvine and a medical degree from UCLA. He trained in pediatrics at Boston Children's Hospital /Harvard Medical School, served in the US Public Health Service, and then was a post-doctoral fellow in infectious diseases while performing immunology research at Stanford University. Kathleen Young Bill and Melinda Gates Foundation Prior to joining the Gates Foundation in 1997, Kathy worked for the Paul Allen Group (the personal investment vehicle for Paul G. Allen, co-founder of Microsoft) for three years. Before relocating to Seattle in 1994, Kathy spent 10 years in the Washington D.C. area working for the Fairfax County Chamber of Commerce and a residential building firm based in Bethesda, Maryland. Kathy, a graduate of IIlinois's Parkland College, now resides in Kirkland, Washington.
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis PROGRAM OF ACTIVITY NIH Visit OF BiLL GATES Octoser 7, 2013 10:15 AM-- 11:00 AM Media Roundtable at Clinical Center (room TBD) 11:05 AM - 11:15 AM Meeting with Dr. Collins (room TBD) 11:15 AM - 12:30 PM Roundtable Discussion with NIH Senior Leadership Medical Board Room, Clinical Center Opening remarks: Francis Collins and Bill Gates Select priorities in global health R&D: state of the science, question to resolve e --HlVand malaria vaccines, and other prevention technologies Lead discussant: Hugh Auchincloss, Principal Deputy Director, NIAID Cliff Lane, Deputy Director for Clinical Research, NIAID Roger Glass, Director, FIC e Understanding the molecular basis of growth and nutrition Lead discussant: Alan Guttmacher, Director, NICHD Greg Germino, Director NIDDK ¢ Point-of-care diagnostics and therapeutics for neglected diseases Lead discussant: Roderic Pettigrew, Director, NIBIB Martha Somerman. Director, NIDCR Chris Austin, Director, NCATS e Integrating NCDs into global health Lead Discussant: Harold Varmus, Director, NCI Gary Gibbons, Director, NHLBI e New partnerships in discovery science: H3Africa and MEPI, the BRAIN initiative Lead Discussant: Eric Green, Director, NHGRI Francis Collins Roger Glass e NIH-PEPAR Implementation Science Partnership Eric Goosby, US Global AIDS Coordinator 12:00 PM-12:30 PM Working Lunch Masur Auditorium, Clinical Center 1:00 PM - 2:00 PM David E. Barmes Global Health Lecture 1:00 PM--- 1:05 PM Introduction by Dr. Collins 1:05 PM -- 1:40 PM Lecture 1:40 PM -- 2:00 PM Q's and A's The C.W. "Bill" Young Center 2:20 PM -- 3:05 PM Innovations in TB Drug Development Clif Barry 3:05 PM -- 3:20 PM Wrap up discussion Dr. Collins and Mr. Gates Chris Wilson Bill and Melinda Gates Foundation Dr. Chris Wilson, director of the Global Health Discovery & Translational Sciences program, leads a team that targets fundamental scientific and technological advances in global health that could lead to new ways to prevent, treat, and diagnose disease. Wilson joined the foundation in 2009 as Deputy Director, Vaccine Discovery and Human Biology, Global Health Discovery. Wilson is a pediatrician and immunologist. He joined the faculty at the University of Washington in 1979 in the Infectious Diseases Division of the Department of Pediatrics and later served as head of the Division of Infectious Diseases, Immunology and Rheumatology. In 1989, he became one of the founding faculty members in the new Department of Immunology, and served as Chairman of the Department of Immunology and head of the graduate program in immunology from 1999-2009. He has also served on a number of national advisory panels, including the Institute of Medicine Vaccine Safety Review Committee (2001-2004) and the National Advisory Council on Child Health and Human Development, the NIH Advisory Committee to the Director, and he co-chaired the NIAID US Immunodeficiency Network Pilot Grant Review Committee. He is an elected fellow of the American Association for the Advancement of Science. Wilson received a bachelor's degree from the University of California, Irvine and a medical degree from UCLA. He trained in pediatrics at Boston Children's Hospital /Harvard Medical School, served in the US Public Health Service, and then was a post-doctoral fellow in infectious diseases while performing immunology research at Stanford University. Kathleen Young Bill and Melinda Gates Foundation Prior to joining the Gates Foundation in 1997, Kathy worked for the Paul Allen Group (the personal investment vehicle for Paul G. Allen, co-founder of Microsoft) for three years. Before relocating to Seattle in 1994, Kathy spent 10 years in the Washington D.C. area working for the Fairfax County Chamber of Commerce and a residential building firm based in Bethesda, Maryland. Kathy, a graduate of IIlinois's Parkland College, now resides in Kirkland, Washington.
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis meb 3/10/23 isdn ss a cabin praia nieces ang 1 communities in Zarb and South Alc. The intervention, taking place in PEPFAR funded ns in he intervention communities, s scheduled to begin by September 30, Enoment nthe population coor (hich fl be ued to measure the HI inince outcome gin next moth POC CD testing with streaming ination of care in Ugands, roe ssid pare ciation evs ina 38 actin Kea str candomied i fe SAMAK FOC voi et to improve Stevenson sso (compared to stand eeare SOC} on nage cra retenion of HV pote puters For pata esting tet seb 3/10/13 ays recat Noh Central igen Yotebeing uptake and retention of PMTCT serves Repub of Congo eactsaned ! 75000 to WHO PMTCT gudeines a South os wat metnadoiogyformensurng PMTCT owes I ge, ety lant gross sd HI esting and SRS ale BESS TOTAL pee, z i : [Simin i a js ao Ri Fa z Ee : Sa0o0, i Bic ii igen Siac ailing rg Ung Ropu: K Cabstcn wih PEBFAA i : - : : wo SS P laphang idea aaaaca T i F oa omen I nen Methadone aa Sabonne for ectng a PEPFAR onding was sapped all these pat unded ough NDA - i i aia eaicion Bari inane : = E = :
-
Dear colleagues, lam delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Please feel free to contact Rob with any Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis Would Melanie Bacon by the person In that you comment 1) the state of 2d discussion. 2eping flexible ry, this format
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. yject Manager for Strategic Planning and Engagement in lam asking Eric to Details on the lunch are forthcoming. Please feel free to contact Rob with any Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis Would Melanie Bacon by the person
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. In that you comment 1) the state of ad discussion. 2eping flexible ry, this format yject Manager for Strategic Planning and Engagement in lam asking Eric to Details on the lunch are forthcoming. Please feel free to contact Rob with any I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis » time. Gray I will be lave provided is outdated, so I'm just trouble Would Melanie Bacon by the person
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis I. Let me know if you need something else.
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Please feel free to contact Rob with any Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis NIH E FAR Co abo at n 2013 mcb 1/10/13 HPTN 071: PopART NIAID Hayes LSHTM PopART South Africa/ Zambia $10,000,000 PEPFAR PEPFAR, NIAID, NIMH, BMGF Randomized study of combination prevention interventions involving 21 communities in Zambia and South Africa. The intervention, taking place in PEPFAR-funded clinics in the intervention communities, is scheduled to begin by September 30. Enrollment in the population cohort (which will be used to measure the HIV incidence outcome)will begin next month. Project SEARCH NIAID Havlir CTU suppl UCSF SEARCH Uganda/Kenya $2,000,000 PEPFAR PEPFAR, WB, NIAID POC CD4 testing with streamlined initiation of care in Uganda. RFA AI-11-003: NIH/PEPFAR Collaboration for Implementation Science and Impact Evaluation (R01) IC PI Grant # Institution Title Country 1st year amount (=request -3.5%) $ Source AIM NIAID Farquhar 99974 UW Assisted partner notification to augment HIV treatment an prevention in Kenya Kenya $650,587.56 OAR introduce assisted partner notification services (aPS) into 18 facilities in Kenya and estimate its capacity to promote HIV testing, identify partners with HIV infection, and link these partners to care NIAID Gray 100031 JHU/Rakai Male Circumcision for HIV Prevention Uganda $964,670.94 PEPFAR To increase MC uptake in a rural setting, particularly in higher risk men, using enhanced messaging, targeted outreach, task shifting, task sharing and mobile camps, and to compare MC uptake, coverage, and client sociodemographic/behavioral characteristics and cost-effectiveness in static clinics versus mobile camps; and conduct a randomized study of the acceptability and safety of EIMC provided by clinical officers (COs) who currently perform adult MC, compared with nurse-midwives (NMWs) who are not currently licensed to perform the procedure NIAID Stringer 100053 UAB/CIDRZ Point-of-care virologic testing to improve outcomes of HIV-infected children
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. lam asking Eric to Details on the lunch are forthcoming. Please feel free to contact Rob with any We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis In that you comment 1) the state of 2d discussion. 2eping flexible ry, this format yject Manager for Strategic Planning and Engagement in
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. lam asking Eric to Details on the lunch are forthcoming. Please feel free to contact Rob with any We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis having to cancel the I hope this is instructive and would be happy to In that you comment 1) the state of 2d discussion.
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Please feel free to contact Rob with any Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis /NIAID) [ -- id.nih.gov> 16:33:48 -0400 1 05:32:15 -0400 Event: Breakfast Mtg. w/ Bill Gates Start Date: 2011-09-13 07:00:00 -0400 End Date: 2011-09-13 08:00:00 -0400 Organizer: Fauci, Anthony (NIH/NIAID) [E] @niaid.nih.gov> Location: Four Seasons Hotel - Georgetown Categories: ,Travel Required Class: X-PERSONAL Date Created: 2019-04-25 16:33:48 -0400 Date Modified: 2024-08-16 05:32:15 -0400 Priority: 5 Attach: 400.eml; 401.eml o meet Bill at the Four Seasons? 7 or 7:30 am perhaps? it can't... get back to you about time on
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal Very helpful. 2eping flexible ry, this format yject Manager for Strategic Planning and Engagement in lam asking Eric to Details on the lunch are forthcoming. Please feel free to contact Rob with any As the schedule conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis
-
Very helpful. In that you comment 1) the state of ad discussion. 2eping flexible ry, this format yject Manager for Strategic Planning and Engagement in lam asking Eric to Details on the lunch are forthcoming. Please feel free to contact Rob with any As the schedule Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis
-
Dear colleagues, I am delighted you are able to join the roundtable discussion with Bill Gates on Monday, October 7, from 11:15 AM-12:30 PM, to take place in the Medical Board Room of the NIH Clinical Center. Attached is the program for the visit, outlining the agenda for the roundtable discussion. The topics are based on conversations with staff from the Global Health Program at the BMGF. I had an opportunity to review the agenda briefly with Bill at the Lasker Awards ceremony (where he and Melinda received the Lakser~Bloomberg award) last week. He is very much looking forward to the discussion. Based on Bill's preferences, we are organizing the roundtable as a conversation, rather than series of presentations. In order to make best use of available time, I have identified lead discussants for each agenda topic. I ask that you comment briefly, not to exceed 3 minutes, on one or several select scientific challenges of relevance to the BMGF: 1) the state of current knowledge and 2) the important questions to resolve. The comments would be intended to seed discussion. Unless you have compelling reasons to include powerpoints, I would suggest avoiding those for this informal conversation. I will try to ensure we cover as much of the agenda as feasible in the time available, while keeping flexible and responsive to Bill's interests and the flow of discussion. Could I also ask lead discussants to confer with colleagues identified under their area, to discuss how to share the time allocated to introduce topics? Given Bill's extensive knowledge in global health R&D and scientific savvy, this format should work well and allow us to relate the diverse scope of exciting science surrounding global health. Bill will be joined at the roundtable by Chris Wilson, Director of the Global Health Discovery & Translational Sciences program (and a member of the ACD), and Kathy Young, Senior Project Manager for Strategic Planning and Engagement in Bill's office. Their bios area attached. We are delighted and honored that Eric Goosby (a former Barmes Lecturer) will join the roundtable. I am asking Eric to comment on the NIH/PEPFAR partnership in implementation science. We will include a working lunch as part of the roundtable discussion Details on the lunch are forthcoming. Prior to the discussion, we also will send a background summary of current IC (and FNIH) activities with the Gates Foundation. Rob Eiss of the FIC has assisted with the planning and organization of this visit. Please feel free to contact Rob with any questions you or your staff may have surrounding the visit. Best regards, Francis
-
Dear Daozhong, Attached is Dr Collins' note on the discussion roundtable with Bill Gates that Dr Tabak and Dr Hudson will join
-
Gray, Are there materials we can send Eric on the implementation science partnership ? Would Melanie Bacon by the person to reach out to Thanks
-
Gray, Are there materials we can send Eric on the implementation science partnership ? Would Melanie Bacon by the person to reach out to Thanks
-
Gray, Are there materials we can send Eric on the implementation science partnership ? Would Melanie Bacon by the person to reach out to Thanks
-
Gray, Are there materials we can send Eric on the implementation science partnership ? Would Melanie Bacon by the person to reach out to Thanks
-
Gray, Are there materials we can send Eric on the implementation science partnership ? Would Melanie Bacon by the person to reach out to Thanks In that you comment 1) the state of 2d discussion. 2eping flexible ry, this format yject Manager for Strategic Planning and Engagement in lam asking Eric to Details on the lunch are forthcoming. Please feel free to contact Rob with any
-
I would have assumed that Eric's own staff would provide these materials since the activities are funded by OGAC. Melanie would be the person to ask about this as she keeps track of these initiatives....but very informally because multiple ICs are actually in charge of their bits and pieces. On the revised visit schedule, wouldn't it make more sense for Francis to have his one-on-one before the press event rather than after? G
-
I would have assumed that Eric's own staff would provide these materials since the activities are funded by OGAC. Melanie would be the person to ask about this as she keeps track of these initiatives....but very informally because multiple ICs are actually in charge of their bits and pieces. On the revised visit schedule, wouldn't it make more sense for Francis to have his one-on-one before the press event rather than after? G
-
I would have assumed that Eric's own staff would provide these materials since the activities are funded by OGAC. Melanie would be the person to ask about this as she keeps track of these initiatives....but very informally because multiple ICs are actually in charge of their bits and pieces. On the revised visit schedule, wouldn't it make more sense for Francis to have his one-on-one before the press event rather than after? G
-
He does have time with Bill prior to the media roundtable, and then again prior to the leadership roundtable --_| will be updating the agenda to reflect There have been a few instances where the background OGAC staff have provided is outdated, so I'm just trouble shooting in case we have information we could provide
-
He does have time with Bill prior to the media roundtable, and then again prior to the leadership roundtable I will be updating the agenda to reflect There have been a few instances where the background OGAC staff have provided is outdated, so I'm just trouble shooting in case we have information we could provide
-
Hi Melanie, I hope things are well Dr Collins will ask Eric Goosby to say a few words about the implementation science partnership, during the roundtable discussion with Bill Gates on Oct 7 I'm staffing Dr Collins for this May I ask, is there any information on progress, from our end, that we might pass to Eric that may help him prepare? Thanks for any assistance you might be Best
-
Hi Melanie, I hope things are well -- Dr Collins will ask Eric Goosby to say a few words about the implementation science partnership, during the roundtable discussion with Bill Gates on Oct 7 I'm staffing Dr Collins for this May I ask, is there any information on progress, from our end, that we might pass to Eric that may help him prepare? Thanks for any assistance you might be Best
-
Hi Melanie, I hope things are well Dr Collins will ask Eric Goosby to say a few words about the implementation science partnership, during the roundtable discussion with Bill Gates on Oct 7 I'm staffing Dr Collins for this May I ask, is there any information on progress, from our end, that we might pass to Eric that may help him prepare? Thanks for any assistance you might be Best
-
Wow - there has been a lot going on, so I'll give you some general info and will attach a list of the current RO1/U01s which we are working on in collaboration. Let me know if you need something else. e NIH began doing limited evaluations for PEPFAR in 2005. e In 2010 we did a collaborative admin supp program where NIH grantees were funded (by OGAC, $10m, and OAR, $3m) to address implantation science topics of particular importance to PEPFAR programming. Six ICs participated: NIAID, NICHD, NIDA, NIMH, NIAAA, NCI, and FIC and 35 -- 1yr supplements were awarded (out of 141 applications -- our investigators really see the importance of this). 18 countries were represented in the research. e Based on the success of this, in FY11 we issued a FOA for 3 year grants addressing PEPFAR related Implementation Science, again funded by OGAC and OAR. 15 grants were awarded in the first half of FY12, through 4 different ICs. They are named in the attached list. e At nearly the same time, NICHD issued a PA for an NIH/PEPFAR collaboration on PMTCT projects. They have begun to set up a research network for those working on these projects, and others in the field. I am double checking on the number awarded. e In addition to these, the large collaborative project which is funded by NIH, OGAC, BMGF and WB, is called PopART, HPTNO71, which is a combination prevention intervention study involving 21 communities (12 in Zambia, 9 in Western Cape, South Africa). The intervention, taking place in PEPFAR-funded clinics in the intervention communities, is scheduled to begin by September 30. Enrollment in the population cohort (which will be used to measure the HIV incidence outcome)will begin next month. DAVID BURNS in NIAID PSP is the Program Officer for this and can give you more details. BMGF works with this as well. Please let me know what other info you would like. Thanks, Melanie
-
Wow - there has been a lot going on, so I'll give you some general info and will attach a list of the current RO1/U01s which we are working on in collaboration. Let me know if you need something else. e NIH began doing limited evaluations for PEPFAR in 2005. e In 2010 we did a collaborative admin supp program where NIH grantees were funded (by OGAC, $10m, and OAR, $3m) to address implantation science topics of particular importance to PEPFAR programming. Six ICs participated: NIAID, NICHD, NIDA, NIMH, NIAAA, NCI, and FIC and 35 -- 1yr supplements were awarded (out of 141 applications -- our investigators really see the importance of this). 18 countries were represented in the research. e -- Based on the success of this, in FY11 we issued a FOA for 3 year grants addressing PEPFAR related Implementation Science, again funded by OGAC and OAR. 15 grants were awarded in the first half of FY12, through 4 different ICs. They are named in the attached list. e At nearly the same time, NICHD issued a PA for an NIH/PEPFAR collaboration on PMTCT projects. They have begun to set up a research network for those working on these projects, and others in the field. I am double checking on the number awarded. e In addition to these, the large collaborative project which is funded by NIH, OGAC, BMGF and WB, is called PopART, HPTNO71, which is a combination prevention intervention study involving 21 communities (12 in Zambia, 9 in Western Cape, South Africa). The intervention, taking place in PEPFAR-funded clinics in the intervention communities, is scheduled to begin by September 30. Enrollment in the population cohort (which will be used to measure the HIV incidence outcome)will begin next month. DAVID BURNS in NIAID PSP is the Program Officer for this and can give you more details. BMGF works with this as well. Please let me know what other info you would like. Thanks, Melanie
-
Wow - there has been a lot going on, so I'll give you some general info and will attach a list of the current R01/U01s which we are working on in collaboration. Let me know if you need something else. · NIH began doing limited evaluations for PEPFAR in 2005. · In 2010 we did a collaborative admin supp program where NIH grantees were funded (by OGAC, $10m, and OAR, $3m) to address implantation science topics of particular importance to PEPFAR programming. Six ICs participated: NIAID, NICHD, NIDA, NIMH, NIAAA, NCI, and FIC and 35 - 1yr supplements were awarded (out of 141 applications - our investigators really see the importance of this). 18 countries were represented in the research. · Based on the success of this, in FY11 we issued a FOA for 3 year grants addressing PEPFAR related Implementation Science, again funded by OGAC and OAR. 15 grants were awarded in the first half of FY12, through 4 different ICs. They are named in the attached list. · At nearly the same time, NICHD issued a PA for an NIH/PEPFAR collaboration on PMTCT projects. They have begun to set up a research network for those working on these projects, and others in the field. I am double checking on the number awarded. · In addition to these, the large collaborative project which is funded by NIH, OGAC, BMGF and WB, is called PopART, HPTN071, which is a combination prevention intervention study involving 21 communities (12 in Zambia, 9 in Western Cape, South Africa). The intervention, taking place in PEPFAR-funded clinics in the intervention communities, is scheduled to begin by September 30. Enrollment in the population cohort (which will be used to measure the HIV incidence outcome)will begin next month. DAVID BURNS in NIAID PSP is the Program Officer for this and can give you more details. BMGF works with this as well. Please let me know what other info you would like. Thanks, Melanie
-
Wow - there has been a lot going on, so I'll give you some general info and will attach a list of the current R01/U01s which we are working on in collaboration. Let me know if you need something else. · NIH began doing limited evaluations for PEPFAR in 2005. · In 2010 we did a collaborative admin supp program where NIH grantees were funded (by OGAC, $10m, and OAR, $3m) to address implantation science topics of particular importance to PEPFAR programming. Six ICs participated: NIAID, NICHD, NIDA, NIMH, NIAAA, NCI, and FIC and 35 - 1yr supplements were awarded (out of 141 applications - our investigators really see the importance of this). 18 countries were represented in the research. · Based on the success of this, in FY11 we issued a FOA for 3 year grants addressing PEPFAR related Implementation Science, again funded by OGAC and OAR. 15 grants were awarded in the first half of FY12, through 4 different ICs. They are named in the attached list. · At nearly the same time, NICHD issued a PA for an NIH/PEPFAR collaboration on PMTCT projects. They have begun to set up a research network for those working on these projects, and others in the field. I am double checking on the number awarded. · In addition to these, the large collaborative project which is funded by NIH, OGAC, BMGF and WB, is called PopART, HPTN071, which is a combination prevention intervention study involving 21 communities (12 in Zambia, 9 in Western Cape, South Africa). The intervention, taking place in PEPFAR-funded clinics in the intervention communities, is scheduled to begin by September 30. Enrollment in the population cohort (which will be used to measure the HIV incidence outcome)will begin next month. DAVID BURNS in NIAID PSP is the Program Officer for this and can give you more details. BMGF works with this as well. tion science partnership, 'end, that we might pass to Eric In that you comment 1) the state of 2d discussion. 2eping flexible ry, this format yject Manager for Strategic Planning and Engagement in Please let me know what other info you would like. Thanks, Melanie
-
A-OK. I would check with Melanie and will copy her here just to save time. Melanie can you pull something off the shelf to help Rob out or would you like some help from OGR? Thanks. Gray
-
Hi Gray, I wasn't really sure what he needed, but I just sent this.... Let me know if you think there is something else I should provide. Melanie
-
Hi Gray, I wasn't really sure what he needed, but I just sent this.... Let me know if you think there is something else I should provide. Melanie
-
Hi Gray, I wasn't really sure what he needed, but I just sent this.... Let me know if you think there is something else I should provide. Melanie
-
Seems just right to me. Rob will let you know if he has any other questions. He is a good guy and we want to help him. Sorry for the duplication. I did not know he had written you already. Many thanks. g
-
Seems just right to me. Rob will let you know if he has any other questions. He is a good guy and we want to help him. Sorry for the duplication. I did not know he had written you already. Many thanks. g
-
As always...>Thanks. Can I call you?
-
As always...>Thanks. Can I call you?
-
If of interest to Dr Tabak, the following was published in the Financial Times the Friday before last. It's well done http://www.ft.com/cms/s/2/dacd1f84-4 1 bf-11e3-b064-00144feabdc0.html#axzz2je9a7qXd November 1, 2013 11:05 am ° ° ° ° ° An exclusive interview with Bill Gates By Richard Waters The internet is not going to save the world, says the Microsoft co-founder, whatever Mark Zuckerberg and Silicon Valley's tech billionaires believe. But eradicating disease just might. << OLE Object: Picture (Device Independent Bitmap) >> ©Amanda Friedman Gates photographed at the Bill & Melinda Gates Foundation in Seattle in September Bill Gates describes himself as a technocrat. But he does not believe that technology will save the world. Or, to be more precise, he does not believe it can solve a tangle of entrenched and interrelated problems that afflict humanity's most vulnerable: the spread of diseases in the developing world and the poverty, lack of opportunity and despair they engender. "I certainly love the IT thing," he says. "But when we want to improve lives, you've got to deal with more basic things like child survival, child nutrition." These days, it seems that every West Coast billionaire has a vision for how technology can make the world a better place. A central part of this new consensus is that the internet is an inevitable force for social and economic improvement; that connectivity is a social good in itself. It was a view that recently led Mark Zuckerberg to outline a plan for getting the world's unconnected 5 billion people online, an effort the Facebook boss called "one of the greatest challenges of our generation". But asked whether giving the planet an internet connection is more important than finding a vaccination for malaria, the co-founder of Microsoft and world's second-richest man does not hide his irritation: "As a priority? It's a joke." Then, slipping back into the sarcasm that often breaks through when he is at his most engaged, he adds: "Take this malaria vaccine, [this] weird thing that I'm thinking of. Hmm, which is more important, connectivity or malaria vaccine? If you think connectivity is the key thing, that's great. I don't." At 58, Bill Gates has lost none of the impatience or intellectual passion he was known for in his youth. Sitting in his office on the shore of Seattle's Lake Washington, the man who dropped out of Harvard University nearly four decades ago and went on to build the world's first software fortune is more relaxed than he was. He has a better haircut and the more pronounced air of self-deprecation that comes with being married and having children who have reached adolescence. But, with the relentless intellectual energy he has always brought to bear on whatever issue is before him, he still can't resist the jibes at ideas he thinks are wrong-headed. After the interview, his minders call to try and persuade me to not report his comments on Zuckerberg: as a senior statesman of the tech and philanthropic worlds, it doesn't help these days to pick fights. There is no getting round the fact, however, that Gates often sounds at odds with the new generation of billionaire technocrats. He was the first to imagine that computing could seep into everyday life, with the Microsoft mission to put a PC on every desk and in every home. But while others talk up the world-changing power of the internet, he is under no illusions that it will do much to improve the lives of the world's poorest. "Innovation is a good thing. The human condition -- put aside bioterrorism and a few footnotes -- is improving because of innovation," he says. But while "technology's amazing, it doesn't get down to the people most in need in anything near the timeframe we should want it to". It was an argument he says he made to Thomas Friedman as The New York Times columnist was writing his 2005 book, The World is Flat, a work that came to define the almost end-of-history optimism that accompanied the entry of China and India into the global labour markets, a transition aided by the internet revolution. "Fine, go to those Bangalore Infosys centres, but just for the hell of it go three miles aside and go look at the guy living with no toilet, no running water," Gates says now. "The world is not flat and PCs are not, in the hierarchy of human needs, in the first five rungs." It is perceptions such as this that have led Gates to spend not just his fortune but most of his time on good works. Other billionaires may take to philanthropy almost as a mark of their social status but, for Gates, it has the force of a moral imperative. The decision to throw himself into causes like trying to prevent childhood deaths in the developing world or improving education in the US was the result of careful ethical calculations, he says. Quoting from an argument advanced by moral philosopher Peter Singer, for instance, he questions why anyone would donate money to build a new wing for a museum rather than spend it on preventing illnesses that can lead to blindness. "The moral equivalent is, we're going to take I per cent of the people who visit this [museum] and blind them," he says. "Are they willing, because it has the new wing, to take that risk? Hmm, maybe this blinding thing is slightly barbaric." << OLE Object: Picture (Device Independent Bitmap) >> ©Sipa Press/Rex Features Gates, aged 25, photographed in 1981 with Microsoft co-founder Paul Allen Through the stroke of pen on cheque book, Gates probably now has the power to affect the lives and wellbeing of a larger number of his fellow humans than any other private individual in history. The Bill & Melinda Gates Foundation, which he set up with his wife in 1997 and where he has been working since leaving his full-time role at Microsoft five years ago, gives away nearly $4bn a year. Much of the money goes toward improving health and fighting poverty in developing countries by tackling malaria or paying for vaccination drives against infectious diseases. This is nearly half as much as the US government spent on global health initiatives in 2012. In many ways, Gates was the archetype for the successful tech entrepreneur, the driven nerd who created an industry with little more than foresight and drive. But to the generation of aspiring techno-visionaries who have followed, the arc of his career no longer has the allure it once did, even if his iconic status is assured. These include people such as Peter Diamandis, a serial entrepreneur who founded the X Prize, which in 1996 offered a $10m award for the first private sector organisation that could create a suborbital space rocket. He likes to think big, and his latest brainstorm involves trying to mine minerals on passing asteroids. According to Diamandis, the Gates Foundation, with its focus on alleviating the suffering of the poorest, smacks of the early 20th-century philanthropy of the robber barons -- men such as Andrew Carnegie and John D Rockefeller, who built and then milked monopolies before spending their later years doling out cash to worthy causes. The latest wave of techno-visionaries, he says, is focused instead on creating whole new industries capable of changing the world. At the height of its powers, the way that Microsoft wielded its PC monopoly to maximise profits from the computing industry made it feared and hated by rivals and start-ups alike. Now, with the PC world on the wane and the company's leadership and direction in doubt, it is spoken of almost with disdain in Silicon Valley -- even though it remains the third biggest tech company based on stock market value, behind Apple and Google. Gates Foundation project Partnering with Coca-Cola and Ghana's health services << OLE Object: Picture (Device Independent Bitmap) >> Coca-Cola is found in the remotest places on the planet. The foundation is working with the multinational beverage company to use their supply chain expertise to help Ghana's health service improve delivery of vaccines to the most difficult-to-access patients, including more efficient management of refrigeration systems. Gates fends off questions about Microsoft, though he says -- contrary to persistent speculation -- that he is not about to step back in to run it as Steve Jobs once returned to revive Apple. He also admits that the company is taking up a much bigger slice of his time than the one day a week to which he signed up after he left. As chairman and a member of the committee searching for a replacement to Steve Ballmer as chief executive, Gates says he still holds regular meetings with some of the company's product groups and that he expects to spend considerable time working with the next boss after an appointment is made. To Diamandis's argument that there is more good to be done in the world by building new industries than by giving away money, meanwhile, he has a brisk retort: "Industries are only valuable to the degree they meet human needs. There's not some -- at least in my psyche -- this notion of, oh, we need new industries. We need children not to die, we need people to have an opportunity to get a good education." It takes more than money to rid the world of a scourge such as polio -- though having buckets of cash certainly helps. Also needed are ambitious thinking, organisational knowhow and the ability to bring new ideas to bear on old problems. These are also the kind of things that go into creating a successful technology company. This time around, though, Bill Gates the CEO has had to take a back seat to a less familiar persona: Bill Gates the diplomat. When the Gates Foundation made polio eradication a priority five years ago, the global anti-polio effort was running into the sand. More than 10 years of progress had given way, at around the turn of the millennium, to a stalemate as vaccination efforts in the countries still harbouring the disease failed to reach the coverage levels needed to push it into extinction. The organisations behind the existing drive -- such as Rotary International, the business group that had long led the effort -- "had sort of naively assumed it was on track, but it wasn't", Gates says. "The idea that business as usual was going to get us there -- it had to be broken out of that, because it wasn't going to succeed. It probably would have been better to just give up than do business as usual. But that would have been horrific." Gates seems to relish nothing more than challenging business as usual, often by applying a dose of more ambitious thinking. It was the same impetus that led him to rethink familiar approaches to philanthropy, throwing his money into the urgent pursuit of solutions to big problems rather than attempting a drip-feed of donations that would amount to little more than a Band-Aid. While the foundations started by the likes of Howard Hughes and pharmaceuticals boss Sir Henry Wellcome are still among the handful of the world's richest decades after their